Zynerba Pharmaceuticals is engaged in pharmaceutically-produced transdermal cannabinoid therapies for neuropsychiatric disorders. Co. is focused on improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome (FXS), autism spectrum disorder (ASD), and 22q11.2 deletion syndrome (22q). Co. is developing Zygel, the pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol. Zygel is being developed as a clear gel with once- or twice-daily dosing and is targeting treatment of behavioral symptoms of FXS, ASD and 22q. The ZYNE stock yearly return is shown above.
The yearly return on the ZYNE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ZYNE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|